Oppenheimer Begins Coverage on ProQR Therapeutics (NASDAQ:PRQR)

Stock analysts at Oppenheimer initiated coverage on shares of ProQR Therapeutics (NASDAQ:PRQR) in a research report issued on Friday,Briefing.com Automated Import reports. The firm set an “outperform” rating and a $15.00 price target on the biopharmaceutical company’s stock. Oppenheimer’s target price suggests a potential upside of 485.94% from the stock’s previous close.

Other research analysts have also recently issued reports about the company. Raymond James raised ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $6.00 to $14.00 in a research note on Tuesday, October 29th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th. Chardan Capital restated a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. StockNews.com cut ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. Finally, JMP Securities restated a “market outperform” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. One research analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, ProQR Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $8.83.

ProQR Therapeutics Trading Down 2.3 %

Shares of NASDAQ:PRQR traded down $0.06 during mid-day trading on Friday, reaching $2.56. The stock had a trading volume of 41,218 shares, compared to its average volume of 213,678. ProQR Therapeutics has a twelve month low of $1.61 and a twelve month high of $4.62. The firm has a market cap of $209.10 million, a PE ratio of -8.00 and a beta of 0.30. The firm has a 50 day simple moving average of $3.26 and a two-hundred day simple moving average of $2.50.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. OneDigital Investment Advisors LLC lifted its stake in shares of ProQR Therapeutics by 37.0% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 15,550 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 7,300 shares during the period. Finally, Privium Fund Management B.V. lifted its position in ProQR Therapeutics by 0.9% during the third quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock worth $10,251,000 after acquiring an additional 51,663 shares during the last quarter. 32.65% of the stock is owned by institutional investors and hedge funds.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).